INO-4800 + Placebo
Phase 2/3Terminated 0 views this week 0 watching💤 Quiet
Interest: 20/100
20
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Coronavirus Infection
Conditions
Coronavirus Infection, Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), COVID-19 Disease
Trial Timeline
Nov 30, 2020 → Sep 13, 2022
NCT ID
NCT04642638About INO-4800 + Placebo
INO-4800 + Placebo is a phase 2/3 stage product being developed by Inovio Pharmaceuticals for Coronavirus Infection. The current trial status is terminated. This product is registered under clinical trial identifier NCT04642638. Target conditions include Coronavirus Infection, Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), COVID-19 Disease.
What happened to similar drugs?
0 of 12 similar drugs in Coronavirus Infection were approved
Approved (0) Terminated (2) Active (10)
Hype Score Breakdown
Clinical
15
Activity
0
Company
5
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04642638 | Phase 2/3 | Terminated |
Competing Products
20 competing products in Coronavirus Infection